Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies
- PMID: 26892034
- PMCID: PMC4839046
- DOI: 10.1007/s00296-016-3436-0
Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies
Abstract
The diverse clinical picture of PsA suggests the need to identify suitable therapies to address the different combinations of clinical manifestations. This review aimed to classify the available biologic agents and new small molecule inhibitors (licensed and nonlicensed) based on their proven efficacy in treating different clinical manifestations associated with psoriasis and PsA. This review presents the level of evidence of efficacy of different biologic treatments and small molecule inhibitors for certain clinical features of treatment of PsA and psoriasis, which was graded in categories I-IV. The literature searches were performed on the following classes of biologic agents and small molecules: TNF inhibitors (adalimumab, etanercept, infliximab, golimumab, certolizumab), anti-IL12/IL23 (ustekinumab), anti-IL17 (secukinumab, brodalumab, ixekizumab), anti-IL6 (tocilizumab), T cell modulators (alefacept, efalizumab, abatacept, itolizumab), B cell depletion therapy (rituximab), phosphodiesterase 4 inhibitor (apremilast) and Janus kinase inhibitor (tofacitinib). A comprehensive table including 17 different biologic agents and small molecule inhibitors previously tested in psoriasis and PsA was generated, including the level of evidence of their efficacy for each of the clinical features included in our review (axial and peripheral arthritis, enthesitis, dactylitis, and nail and skin disease). We also proposed a limited set of recommendations for a sequential biologic treatment algorithm for patients with PsA who failed the first anti-TNF therapy, based on the available literature data. There is good evidence that many of the biologic treatments initially tested in psoriasis are also effective in PsA. Further research into both prognostic biomarkers and patient stratification is required to allow clinicians the possibility to make better use of the various biologic treatment options available. This review showed that there are many potentially new treatments that are not included in the current guidelines that can be used for selected categories of patients based on their disease phenotype, clinician experience and access to new biologic therapies.
Keywords: Biologic treatments; Level of evidence of biologic agents efficacy; Psoriasis; Psoriatic arthritis; Small molecule inhibitors.
Similar articles
-
Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.BioDrugs. 2013 Aug;27(4):359-73. doi: 10.1007/s40259-013-0025-6. BioDrugs. 2013. PMID: 23580094 Review.
-
TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.BioDrugs. 2005;19(1):47-57. doi: 10.2165/00063030-200519010-00006. BioDrugs. 2005. PMID: 15691217 Review.
-
New targets in psoriatic arthritis.Rheumatology (Oxford). 2016 Dec;55(suppl 2):ii30-ii37. doi: 10.1093/rheumatology/kew343. Rheumatology (Oxford). 2016. PMID: 27856658 Review.
-
Emerging drugs for psoriatic arthritis.Expert Opin Emerg Drugs. 2016;21(1):69-79. doi: 10.1517/14728214.2016.1146679. Epub 2016 Feb 15. Expert Opin Emerg Drugs. 2016. PMID: 26807876 Review.
-
Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.J Med Econ. 2016;19(1):34-43. doi: 10.3111/13696998.2015.1086774. Epub 2015 Sep 30. J Med Econ. 2016. PMID: 26337538
Cited by
-
In the Real World: Infections Associated with Biologic and Small Molecule Therapies in Psoriatic Arthritis and Psoriasis.Curr Rheumatol Rep. 2019 Jun 6;21(7):36. doi: 10.1007/s11926-019-0832-y. Curr Rheumatol Rep. 2019. PMID: 31172303 Review.
-
TNFR2 Depletion Reduces Psoriatic Inflammation in Mice by Downregulating Specific Dendritic Cell Populations in Lymph Nodes and Inhibiting IL-23/IL-17 Pathways.J Invest Dermatol. 2022 Aug;142(8):2159-2172.e9. doi: 10.1016/j.jid.2021.12.036. Epub 2022 Jan 26. J Invest Dermatol. 2022. PMID: 35090950 Free PMC article.
-
Dual Role of Act1 in Keratinocyte Differentiation and Host Defense: TRAF3IP2 Silencing Alters Keratinocyte Differentiation and Inhibits IL-17 Responses.J Invest Dermatol. 2017 Jul;137(7):1501-1511. doi: 10.1016/j.jid.2016.12.032. Epub 2017 Mar 6. J Invest Dermatol. 2017. PMID: 28274739 Free PMC article.
-
A Real-World Study to Assess the Effectiveness of Itolizumab in Patients with Chronic Plaque Psoriasis.Indian Dermatol Online J. 2017 Jul-Aug;8(4):246-249. doi: 10.4103/idoj.IDOJ_330_16. Indian Dermatol Online J. 2017. PMID: 28761839 Free PMC article.
-
Choosing the Appropriate Target for the Treatment of Psoriatic Arthritis: TNFα, IL-17, IL-23 or JAK Inhibitors?Mediterr J Rheumatol. 2022 Apr 15;33(Suppl 1):150-161. doi: 10.31138/mjr.33.1.150. eCollection 2022 Mar. Mediterr J Rheumatol. 2022. PMID: 36127928 Free PMC article. Review.
References
-
- Gladman DD, Mease PJ. Towards international guidelines for the management of psoriatic arthritis. J Rheumatol. 2006;33(7):1228–1230. - PubMed
-
- Ash Z, Gaujoux-Viala C, Gossec L, Hensor EM, FitzGerald O, Winthrop K, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2012;71(3):319–326. doi: 10.1136/ard.2011.150995. - DOI - PubMed
-
- Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52(10):3279–3289. doi: 10.1002/art.21306. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous